Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Inks Purchasing Deal with Premier

NEW YORK (GenomeWeb) – NeoGenomics today announced a three-year national group purchasing agreement with Premier to provide the healthcare alliance's members with full access to NeoGenomics' menu of oncology testing services. 

The deal makes Ft.Myers, Florida-based NeoGenomics the first specialized oncology reference laboratory to be a preferred in-network lab option for all Premier member hospitals, cancer centers, pathology groups, and oncology physician providers, the company said. Premier is a healthcare group purchasing organization composed of about 3,600 hospitals and 12,000 other provider members. 

The agreement gives its members access to NeoGenomics' services such as the next-generation sequencing-based NeoType Cancer Profiles. The NeoType tumor-specific profiling menu was recently expanded to include profiles for head and neck tumors, pancreatic cancer, liver cancer, sarcoma, and cancers of unknown primary. A complete analysis of somatic mutations in BRCA1 and 2 are now also a part of breast, ovarian, and pancreatic cancer profiling. 

NeoGenomics' shares on the Nasdaq rose about 6 percent to $6.29 in morning trading today.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.